Blueprint Medicines, Inc. (BPMC)

Oncology Corporate Profile

Stock Performance

15.8900
-1.4200

HQ Location

215 First Street
Cambridge, MA 2142

Company Description

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

Website: http://www.blueprintmedicines.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BLU-285®PDGFR®D842V inhibitorGastrointestinal Stromal Tumors (GIST)I
BLU-554PDGFR®D842V inhibitorHepatocellular carcinoma (HCC)I
BLU-667RET inhibitorNon Small Cell Lung Cancer (NSCLC)I
BLU-667RET inhibitorThyroid cancerI

Source: http://www.blueprintmedicines.com/

Recent News Headlines

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/26/2017 06:17 am

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/8/2017 12:17 pm

5/8/2017 12:17 pm

5/8/2017 12:17 pm

5/8/2017 12:17 pm

5/5/2017 06:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

5/3/2017 12:17 am

4/27/2017 06:17 am

4/27/2017 06:17 am

4/26/2017 06:17 am